All News

RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
abdominal-pain-2821941_640.jpg

Manifestations of Systemic Sclerosis Sine Scleroderma

Jack Cush, MD

Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%). 

Read Article
RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
ild.jpg

Scary Outcomes with Systemic Sclerosis Sine Scleroderma

Jack Cush, MD

The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.

Read Article
AE, Side effects

Check SSc-ILD Patients on Nintedinib for Malnutrition

MedPage Today

During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.

Read Article
342 systemic sclerosis pts, ~32% report reproductive probs: -early menopause onset (45 vs 48y) -menopause effected by SSc onset & digital ulcers -More spont Abs(12 vs 4%), premies (22 vs 6%), low birth Wt (27 vs 5%), C-section (49 vs 19%); NOT Infertility https://t.co/Tjjl9sxtja https://t.co/LKzyGR0mlE

Links:

Dr. John Cush RheumNow ( View Tweet)
Johns Hopkins & Univ Pittsburgh Scleroderma compared autoantibodies in 676 SSc pts w/ hx of cancer to 687 SSc controls without CA. Anti-POLR3 & anti-Ro52 assoc w. significantly increased cancer risk; Centromere & U1RNP had a decreased cancer risk https://t.co/z6HfRR7PWs https://t.co/zISZlgHGjd

Links:

Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc. https://t.co/DMZTLKwmHv https://t.co/2bXqMt7H1z

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC

Links:

Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc. https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at: - Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes - Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : #ClinicalPearl Rx of #scleroderma #ILD -add another drug. MMF, then Cyclo, Rituximab, ?tocilizumab; if progressive fibrosis then #Nintedanib ?Pirfenidone Small RCT of MMF v Tacrolimus - looked the same -helpful if MMF fails, future pregnancy OP0240 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : A shame. Pts with #scleroderma are dying waiting for organ transplant- we should list and work them up for Tx earlier. PAH Pts May do worse @eular_org #EULAR2023 @RheumNow OP0241

Dr. John Cush RheumNow ( View Tweet)

Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE

Links:

Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0

Links:

Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data analysis of 1,830 scleroderma (SSc) pts & 27,981 controls showed increased incidence of SSc hospitalized w/ heart failure of 3.5%, 5.3%, & 9.7% (at 3, 5, 10 yrs). SSc patients had an increased risk of HF (adjusted HR 3.26) https://t.co/4WcHfiTJVF https://t.co/rW3J5aQdlS

Links:

Dr. John Cush RheumNow ( View Tweet)
Scleroderma therapeutics: we’re actually getting some choices! Christian Dejaco #EULAR2023 @RheumNow https://t.co/sW2FBY0RqS
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×